Beneficial Ownership Report · SCHEDULE 13G
First Tracks Biotherapeutics, Inc.
TRAXNASDAQEQUITYCurrent
Beneficial Ownership Report
Company context
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗